Since 1976, LKC Technologies established itself as the industry leader in visual electrophysiology products.
With the introduction of the RETeval® device, the world’s first and only hand-held, battery powered, portable and non-invasive device for use on dilated or non-dilated patients, LKC has brought the latest in technology and electrophysiology to over thirty major eye hospitals in the United States.
O RETeval handheld ERG is perfect for pediatric, adult, and geriatric patients alike. The device can be used with the patented non-invasive LKC’s Sensor Strips, providing improved patient comfort and faster testing time. The RETeval device is FDA cleared and offers integrated age-adjusted reference intervals ranges based on a 500+ patient clinical trial, which provides valuable input to physicians to aid in the diagnosis and monitoring of ophthalmic disorders.
According to Dr. Kara Khalatbari, MD (US Retina member) in the Charlotte NC area, the RETeval device and electrophysiology is a “game changer” for his practice. Dr. Khalatbari uses this device on patients with diabetic retinopathy, macular degeneration, glaucoma, inherited retinal degeneration, CRVO, and other ophthalmic disorders.
During the 2019 US Retina webinar Implementation, Use and Benefits of Electrophysiology in a Busy Practice, Dr. Khalatbari highlighted how easy it was to train his technicians on how to operate the device and to assist in the interpretation of the test results with no impact to patient flow. He also mentioned how this device adds a full and objective functional assessment of the patient and helps him to determine a comprehensive timeline for a patient’s future visit.
In the video below, Dr. Khalatbari discusses how he uses the ERG Glaucoma testing on the RETeval device to guide his surgical decision-making.
A 66 year old male patient presented with blurred vision several years after cataract surgery. OCT revealed optic nerve damage but the difference between the eyes was indistinguishable. Dr. Khalatbari used the RETeval Glaucoma test, which uses a photopic negative response to assess the relative responses of the ganglion cell layers. The technology of the RETeval unit compares both the P-ration and the W-ratio for a comprehensive view of the relative response of the ganglion cell to overall bi-polar retinal function.
This approach allowed Dr. Khalatbari to assess early glaucoma atrophy damage with visual field loss, and thus the confidence to proceed with premium cataract surgery.
Warning: This product can expose you to chemicals including lead, which is known to the State of California to cause cancer and birth defects or other reproductive harm. For more information go to 
